|
EURONEXT BRUSSELS
Depuis sa création
en 1980, GIMV est devenue le principal fournisseur de capital-risque et
créateur d’entreprises en Belgique et, de ce fait, est aujourd’hui
un des grands acteurs du marché européen et international.
GIMV investit aussi bien dans la technologie d’information et de communication,
que dans des entreprises de biotechnologie ou de capital de croissance
et des Management Buy-outs (MBO’s) d’entreprises dans des secteurs traditionnels,
et ce, tant en Belgique qu’à l’étranger. Avec la combinaison
des entreprises de son propre portefeuille et des activités de fonds
pour des tiers, GIMV aujourd’hui gère plus d'1,4 milliard d'euros.
GIMV est cotée à l'Euronext Brussel depuis 1997.
GIMV
: Business update : first 9 months of the 2006 – 2007 financial year
(23/11/06 08:00 CET)
As
GIMV will make the transition this year from a financial year from 1 April
to 31 March, the current financial year will be extended to 31 March 2007.
Consequently the publication dates for the half-yearly and annual results
have been adjusted. In addition, GIMV has opted to provide a quarterly
update on its activities without however publishing a complete result.
All figures in the press release below refer to figures according to the
limited consolidation of GIMV (non-audited figures)[1].
KEY
ELEMENTS
Investments
Total
investments over the first nine months of 85.9 million euro, of which 78.6
million
euro on own balance sheet1 (respectively 21.1 million euro investments
in the third quarter, completely on GIMV’s own balance sheet)
Over
the first 9 months, 31.0 million euro was invested in Corporate Investment,
34.5
million euro in ICT, and 20.4 million euro in Life Sciences (respectively
3.2 million
euro,
10.3 million euro, and 7.6 million euro in the third quarter)
33%
in Belgium, 57% in the rest of Europe and 10% in the United States
47%
(40.6 million euro) in 13 new direct investments, 37% (32.0 million euro)
in direct
follow-up
investments and 16% (13.4 million euro) in third-party funds (respectively
66%, 16%, and 18% in the third quarter
The
principal investments in the third quarter (? 1 million euro): AbLynx,
ActoGenix,
Clear2Pay,
Peakadilly, Plexxikon and VirtenSys
Divestments
Total
revenues from divestments over the first 9 months amount to 116.9
million
euro (of which 17.0 million euro in the third quarter). In addition, the
participations sold
also
generated 22.5 million euro in dividends, interests and management fees
(of which 0.5 million euro in the third quarter) for GIMV in the first
9 months of 2006
79%
Corporate Investment, 7% ICT and 10% Life Sciences (respectively 67%, 23%,
and 10%
in
the third quarter)
7%
loans, 6% listed participations, 76% unlisted participations and 11% Funds
Divestments
over the first 9 months return 43.1% more than their book value as of 31
December
2005,
and 51.5% more than their original acquisition cost
The
principal divestments in the third quarter (? 1 million euro): Capco, Food
Partners,
[1]The
limited consolidation gives a more realistic view of the group and must
allow investors and other interested parties to understand and follow the
financial performance of the group. All GIMV’s participations are valued
at the fair value in accordance with the international valuation guidelines
for private equity companies in the limited consolidation.
GIMV
investit dans l'entreprise belge de biotechnologie Actogenix
(19/09/06 08:12 CET)
GIMV, Biotech
Fonds Vlaanderen et Life Sciences Partners investissent ensemble 11,5 millions
d’euros dans le premier tour de table (Series?A) d'ActoGenix, une start-up
belge de biotechnologie et spin-off de l'Institut interuniversitaire flamand
pour la biotechnologie (VIB). GIMV et Life Sciences Partners sont les deux
principaux co-investisseurs.
|
